BACKGROUND: Activation rate (AR) gradients develop during ventricular fibrillation (VF), with the highest AR on the surface near Purkinje system (PS) terminals (endocardium in humans and rabbits and epicardium in pigs). The application of glibenclamide to block adenosine triphosphate (ATP)-sensitive potassium current (IK(ATP)) before VF induction eliminates transmural AR gradients and prevents the induction of sustained arrhythmia. It remains unclear whether the PS, which is resistant to ischemia, is also a factor in AR heterogeneity. OBJECTIVE: To dissect IK(ATP) and PS contributions to AR gradients during VF by using detailed computer simulations. METHODS: We constructed rabbit ventricular models with either subendocardial or subepicardial PS terminals. Physiologically relevant IK(ATP) gradients were implemented, and early VF was induced and observed. RESULTS: Prominent AR gradients were observed only in models with large IK(ATP) gradients. The critical underlying factor of AR gradient maintenance was refractoriness in low-IK(ATP) regions, which blocked the propagation of action potentials from high-IK(ATP) regions. The PS played no role in transmural AR gradient maintenance, but did cause local spatial heterogeneity of AR on the surface adjacent to terminals. Simulated glibenclamide application during VF led to spontaneous arrhythmia termination within a few seconds in most cases, which builds on previous experimental findings of anti-VF properties of glibenclamide pretreatment. CONCLUSION: Differential IK(ATP) across the ventricular wall is an important factor underlying AR gradients during VF; thus, higher epicardial AR in pigs is most likely due to an abundance of epicardial IK(ATP). For terminating early VF, our results suggest that IK(ATP) modulation is a stronger target than Purkinje ablation.
BACKGROUND: Activation rate (AR) gradients develop during ventricular fibrillation (VF), with the highest AR on the surface near Purkinje system (PS) terminals (endocardium in humans and rabbits and epicardium in pigs). The application of glibenclamide to block adenosine triphosphate (ATP)-sensitive potassium current (IK(ATP)) before VF induction eliminates transmural AR gradients and prevents the induction of sustained arrhythmia. It remains unclear whether the PS, which is resistant to ischemia, is also a factor in AR heterogeneity. OBJECTIVE: To dissect IK(ATP) and PS contributions to AR gradients during VF by using detailed computer simulations. METHODS: We constructed rabbit ventricular models with either subendocardial or subepicardial PS terminals. Physiologically relevant IK(ATP) gradients were implemented, and early VF was induced and observed. RESULTS: Prominent AR gradients were observed only in models with large IK(ATP) gradients. The critical underlying factor of AR gradient maintenance was refractoriness in low-IK(ATP) regions, which blocked the propagation of action potentials from high-IK(ATP) regions. The PS played no role in transmural AR gradient maintenance, but did cause local spatial heterogeneity of AR on the surface adjacent to terminals. Simulated glibenclamide application during VF led to spontaneous arrhythmia termination within a few seconds in most cases, which builds on previous experimental findings of anti-VF properties of glibenclamide pretreatment. CONCLUSION: Differential IK(ATP) across the ventricular wall is an important factor underlying AR gradients during VF; thus, higher epicardial AR in pigs is most likely due to an abundance of epicardial IK(ATP). For terminating early VF, our results suggest that IK(ATP) modulation is a stronger target than Purkinje ablation.
Authors: Talha A Farid; Krishnakumar Nair; Stephéne Massé; Mohammed Ali Azam; Ange Maguy; Patrick F H Lai; Karthikeyan Umapathy; Paul Dorian; Vijay Chauhan; András Varró; Abdul Al-Hesayen; Menashe Waxman; Stanley Nattel; Kumaraswamy Nanthakumar Journal: Circ Res Date: 2011-10-06 Impact factor: 17.367
Authors: Kumaraswamy Nanthakumar; Jian Huang; Jack M Rogers; Philip L Johnson; Jonathan C Newton; Greg P Walcott; Robert K Justice; Dennis L Rollins; William M Smith; Raymond E Ideker Journal: Circ Res Date: 2002-10-18 Impact factor: 17.367
Authors: Vadim V Fedorov; Alexey V Glukhov; Christina M Ambrosi; Geran Kostecki; Roger Chang; Deborah Janks; Richard B Schuessler; Nader Moazami; Colin G Nichols; Igor R Efimov Journal: J Mol Cell Cardiol Date: 2011-05-07 Impact factor: 5.000
Authors: Richard D Walton; Marine E Martinez; Martin J Bishop; Mélèze Hocini; Michel Haïssaguerre; Gernot Plank; Olivier Bernus; Edward J Vigmond Journal: Cardiovasc Res Date: 2014-07-03 Impact factor: 10.787
Authors: Tobias Bruegmann; Patrick M Boyle; Christoph C Vogt; Thomas V Karathanos; Hermenegild J Arevalo; Bernd K Fleischmann; Natalia A Trayanova; Philipp Sasse Journal: J Clin Invest Date: 2016-09-12 Impact factor: 14.808
Authors: James Rush Priest; Charles Gawad; Kristopher M Kahlig; Joseph K Yu; Thomas O'Hara; Patrick M Boyle; Sridharan Rajamani; Michael J Clark; Sarah T K Garcia; Scott Ceresnak; Jason Harris; Sean Boyle; Frederick E Dewey; Lindsey Malloy-Walton; Kyla Dunn; Megan Grove; Marco V Perez; Norma F Neff; Richard Chen; Katsuhide Maeda; Anne Dubin; Luiz Belardinelli; John West; Christian Antolik; Daniela Macaya; Thomas Quertermous; Natalia A Trayanova; Stephen R Quake; Euan A Ashley Journal: Proc Natl Acad Sci U S A Date: 2016-09-28 Impact factor: 11.205